Clinical Chemistry and Laboratory Medicine (CCLM)
Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Editor-in-Chief: Plebani, Mario
Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.
IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition
SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238
Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
1INSERM U563, Department of Lipoproteins and Lipid Mediators, CHU, Toulouse, France and Department of Infectious Diseases, Université Paul Sabatier, CHU, Toulouse, France
2INSERM U563, Department of Lipoproteins and Lipid Mediators, CHU, Toulouse, France
3Department of Infectious Diseases, Université Paul Sabatier, CHU, Toulouse, France
4INSERM U563, Department of Lipoproteins and Lipid Mediators, CHU, Toulouse, France
5Department of Infectious Diseases, Université Paul Sabatier, CHU, Toulouse, France
6INSERM U563, Department of Lipoproteins and Lipid Mediators, CHU, Toulouse, France
Citation Information: Clinical Chemical Laboratory Medicine. Volume 45, Issue 7, Pages 815–821, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: 10.1515/CCLM.2007.140, July 2007
- Published Online:
Active anti-HIV therapy can induce hypertriglyceridemia, low high-density lipoprotein (HDL) and insulin resistance, eventually accompanied by clinical lipodystrophy, associated loss of subcutaneous adipose tissue and an increase in abdominal adiposity. The frequency of these metabolic disorders is approximately 50% and host genetic factors might confer particular susceptibility. Variants of apolipoproteins (apo) A5 and C3, interacting with APOE genotypes, have been associated with the severity of antiretroviral therapy-induced dyslipidemia and with occurrence of lipodystrophy, and for APOC3, with objective criteria of fat redistribution. Genetic polymorphisms of the nuclear transcription-factor sterol response element-binding proteins (SREBP1c) and of tumor necrosis factor-α (TNFα) have yielded contrasting results. Other candidate genes will be explored to define a pharmacogenomic strategy to identify patients at high risk of metabolic disorders upon antiretroviral therapy.
Clin Chem Lab Med 2007;45:815–21.
Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.